Curt LaBelle

TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs.

Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT.

Endoscopic Technologies, Inc. manufactured and distributed medical devices. Its product lines span three cardiac surgery disciplines including surgical radio frequency ablation, valve replacement or repair, and coronary artery bypass grafting. The company was founded in 1996 and was headquartered in San Ramon, CA.

Vidacare Corp. develops, manufactures, and markets intraosseous access devices for vascular access and bone biopsies. The company was founded by Eric Eisbrenner, Jim Thomsen, and Larry Miller on March 29, 2002 and is headquartered in San Antonio, TX.

Global Health Investment Advisors LLC operates as an alternative investment manager. The company was founded in 2015 and is headquartered in New York, NY.

Alydia Health, Inc. operates as medical device company which provides solution to postpartum hemorrhage. The company was founded by Nathan Bair and Jessie Becke on May 8, 2018 and is headquartered in Menlo Park, CA.

Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million.

Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York.

Ophirex, Inc. develops antidotes to snakebite. The company was founded by Jerry D. Harrison and Matthew Lewin and is headquartered in Corte Madera, CA.

NuVasive Clinical Services Monitoring, Inc. provides onsite and web-based monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It facilitates the surgical process and reduces surgical risk by providing critical information and alerts to surgeons of potential harm or compromise to the spinal cord or neural structures. The company was founded by Roger Conley in 2000 and is headquartered in San Diego, CA.

SafeOp Surgical, Inc. operates as a medical device company. It offers portable neuro monitoring devices that enable the detection of nerve damage, such as positioning effect, an injury to peripheral nerves related to patient positioning during surgery or prolonged sedation. The company was founded in 2011 and is headquartered in Hunt Valley, MD.

IanTech, Inc. develops ophthalmic devices for cataract surgery. Its products include miLoop, miPhaco, miMissions, and miResources. The company was founded by Luke Clauson and Sean Ianchulev and is headquartered in Reno, NV.

Serum Institute of India Pvt Ltd. engages in the production and exportation of anti-cancer products and viral vaccines. Its products include bacterial vaccines, recombinant and combination vaccines, viral vaccines, influenza vaccines. uro-oncology, and polysaccharide conjugate vaccine. The company was founded by Cyrus S. Poonawalla in 1966 and is headquartered in Pune, India.

Maternal Newborn Health Innovations Corp. is a company based in Kinnelon, NJ. Gary M. Cohen has been the CEOs since incorporation. Maternal Newborn Health Innovations Corp. was founded by Gary M. Cohen.

CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb.

Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA.

AXA Investment Managers (Paris) SA (Investment Management) (AXA IM) is the structured finance division of AXA Investment Managers (Paris) SA, itself a subsidiary of AXA SA (XP: CS) in France. Created in 2000, the firm is a dedicated buy-side platform which is organized into investment teams specializing in managing structured finance products including corporate credit, structured credit invest, asset backed securities and insurance linked securities for a range of clients including pension funds, corporations, governments, institutions and insurance companies. Their Responsible Investment team utilizes AXA Investment Managers' multi-expert model and RI Search© to conducts ESG research that informs investment decision-making and active stewardship practices.

Global Health Investment Fund seeks investment opportunities in global health technologies. The fund invests in new drugs & vaccines, emerging diagnostic tools, child-friendly formulations of existing products, expanding manufacturing capacity and other applications. It provides financing in the form of mezzanine for later-stage capital requirements.